A 10-to-20-patient open-label study is a modest clinical bet, but the mechanistic logic behind SALIENT-AD is what makes it worth watching. CytoDyn has enrolled the first participant in its Phase 2a trial of leronlimab in early-stage Alzheimer’s disease, run in collaboration with Weill Cornell Medicine. The design is deliberately small and exploratory, which is honest given how early the CCR5-in-neuroinflammation hypothesis still is. What the trial lacks in size it attempts to compensate for with imaging precision: the primary endpoint measures changes in brain inflammation and microglial activation using advanced PET imaging, the same kind of quantitative tool that has been used to distinguish patients with early Alzheimer’s from healthy controls in prior translational work.
The rationale centers on CCR5, a chemokine receptor that leronlimab blocks by binding directly to the receptor on immune cells. Preclinical evidence links CCR5 to synaptic plasticity, microglial signaling, and blood-brain barrier stability. That is a biologically plausible case for immune-mediated benefit, but it sits well upstream of any clinical proof. Patients over 50 with biomarker-confirmed early-stage disease will receive weekly subcutaneous leronlimab for 12 weeks. Secondary endpoints span cognitive assessments, blood-based neurodegeneration biomarkers, and MRI-based measures of blood-brain barrier integrity, giving the team multiple biological windows even at this scale.
The Alzheimer’s landscape has become notably more competitive. Both donanemab and lecanemab now carry FDA approval for early symptomatic disease, targeting amyloid-beta. Leronlimab approaches the same population from a different angle entirely, aiming at neuroinflammation rather than plaque clearance. Whether that distinction becomes a complement or a competitor to anti-amyloid therapy is a question SALIENT-AD cannot answer at this size, but it can generate the imaging and biomarker signals needed to justify a larger randomized design. CytoDyn also notes that its primary commercial attention remains on the CLOVER Phase 2 study in metastatic colorectal cancer, which completed enrollment at just over 60 patients across seven U.S. sites, so this Alzheimer’s collaboration is structured as exploratory without diverting the company’s main regulatory focus.
The single result worth tracking from SALIENT-AD is the PET-measured change in microglial activation at 12 weeks. That readout will either establish a pharmacodynamic signal that justifies CCR5 blockade as a neuroinflammatory intervention, or it will close the door on this mechanism in a disease setting where the amyloid-targeting field has already claimed the regulatory runway for early-stage patients.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
